(Q37890208)

24 August 2017

1 reference

title

Changing pathology with changing drugs: tumors of the gastrointestinal tract (English)

1 reference

24 August 2017

0 references

2

Jean-François Fléjou

1 reference

24 August 2017

Pascale Cervera

1

1 reference

24 August 2017

publication date

15 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

78

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

76-89

1 reference

Systemic cancer therapy: evolution over the last 60 years

24 August 2017

cites work

1 reference

21 January 2018

Cancer statistics, 2008

1 reference

21 January 2018

The Hallmarks of Cancer

1 reference

Treating cancer by blocking cell signals

21 January 2018

1 reference

Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.

21 January 2018

1 reference

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

A targeted approach to reducing lung cancer mortality

21 January 2018

1 reference

Targeted therapy of cancer: new roles for pathologists in colorectal cancer

21 January 2018

1 reference

Genetic and molecular diversity of colon cancer hepatic metastases.

21 January 2018

1 reference

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

21 January 2018

1 reference

Interphase FISH as a new tool in tumor pathology

21 January 2018

1 reference

EGFR antagonists in cancer treatment

21 January 2018

1 reference

The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis

21 January 2018

1 reference

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody

21 January 2018

1 reference

IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype

21 January 2018

1 reference

Untangling the ErbB signalling network

21 January 2018

1 reference

TKI-31 inhibits angiogenesis by combined suppression signaling pathway of VEGFR2 and PDGFRbeta

21 January 2018

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

The role of hypoxia-inducible factors in cancer

21 January 2018

1 reference

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

21 January 2018

1 reference

Novel agents on the horizon for cancer therapy

21 January 2018

1 reference

Antisense cancer therapy: the state of the science

21 January 2018

1 reference

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

Novel oncogenic protein kinase inhibitors for cancer therapy

21 January 2018

1 reference

On future's doorstep: RNA interference and the pharmacopeia of tomorrow

21 January 2018

1 reference

Monoclonal antibody mechanisms of action in cancer.

21 January 2018

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability

21 January 2018

1 reference

Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer

21 January 2018

1 reference

Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases.

21 January 2018

1 reference

Clinical implications of microsatellite instability in sporadic colon cancers

21 January 2018

1 reference

The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer

21 January 2018

1 reference

Adjuvant chemotherapy for stages II, III and IV of colon cancer

21 January 2018

1 reference

Epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

Epothilones in breast cancer: review of clinical experience

21 January 2018

1 reference

Biology of interactions: antiepidermal growth factor receptor agents

21 January 2018

1 reference

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

Molecular biology in clinical cancer research: the example of digestive cancers

21 January 2018

1 reference

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

PIK3CA cancer mutations display gender and tissue specificity patterns.

21 January 2018

1 reference

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?

21 January 2018

1 reference

Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases

21 January 2018

1 reference

Nuclear EGFR contributes to acquired resistance to cetuximab

21 January 2018

1 reference

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

21 January 2018

1 reference

Isolation of a tumor factor responsible for angiogenesis

21 January 2018

1 reference

Regulation of angiogenesis by hypoxia: role of the HIF system

21 January 2018

1 reference

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

21 January 2018

1 reference

The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain

21 January 2018

1 reference

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

21 January 2018

1 reference

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

21 January 2018

1 reference

A novel germ line juxtamembrane Met mutation in human gastric cancer

21 January 2018

1 reference

Met, metastasis, motility and more

21 January 2018

1 reference

How to make tubes: signaling by the Met receptor tyrosine kinase

21 January 2018

1 reference

Molecular targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma

21 January 2018

1 reference

Pathogenesis of hepatocellular carcinoma and molecular therapies.

21 January 2018

1 reference

Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas.

21 January 2018

1 reference

New directions in the management of advanced pancreatic cancer: a review

21 January 2018

1 reference

Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.

21 January 2018

1 reference

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

21 January 2018

1 reference

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases

21 January 2018

1 reference

Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas

21 January 2018

1 reference

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

21 January 2018

1 reference

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

21 January 2018

1 reference

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

21 January 2018

1 reference

Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor

21 January 2018

1 reference

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib

21 January 2018

1 reference

Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.

21 January 2018

1 reference

Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.

21 January 2018

1 reference

Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.

21 January 2018

1 reference

21 January 2018

KIT mutations in GIST.

1 reference

Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.

21 January 2018

1 reference

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

RAF/RAS oncogenes and mismatch-repair status

21 January 2018

1 reference

Hepatocellular Carcinoma: Trends of Incidence and Survival in Europe and the United States at the End of the 20th Century

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000315535

1 reference

24 August 2017

1 reference